OS Therapies (OSTX) Long-Term Debt Issuances (2023 - 2026)
OS Therapies' (OSTX) quarterly Long-Term Debt Issuances came in at $1.8 million in Q1 2026, down 81.65% YoY from $10.0 million in Q1 2025, and up 136.7% on a QoQ basis from -$5.0 million in Q4 2025.
OS Therapies (OSTX) Long-Term Debt Issuances (2023 - 2026) Analysis & Trends
OS Therapies (OSTX) has 4 years of Long-Term Debt Issuances data on file, last reported at $1.8 million in Q1 2026.
- Quarterly Long-Term Debt Issuances fell 81.65% year-over-year to $1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.2 million (down 129.44% YoY) and the FY2025 annual result came in at $5.0 million, up 233.11% from the prior year.
- Long-Term Debt Issuances rose to $1.8 million in Q1 2026, from -$5.0 million in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of $10.0 million in Q1 2025 to a low of -$7.0 million in Q2 2025.
- A 4-year average of $1.0 million and a median of $775000.0 in 2023 frame the typical range for Long-Term Debt Issuances.
- The widest YoY moves for Long-Term Debt Issuances: up 1231.56% in 2025, down 1033.33% in 2025.
- Tracing OSTX's Long-Term Debt Issuances over 4 years: stood at $1.1 million in 2023, then dropped by 29.91% to $750000.0 in 2024, then slumped by 766.67% to -$5.0 million in 2025, then jumped by 136.7% to $1.8 million in 2026.
- The last three Long-Term Debt Issuances figures came in at $1.8 million (Q1 2026), -$5.0 million (Q4 2025), and $7.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | OS Therapies | 19.46 Mn | 19.46 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.84 Mn |
| Mar 31, 2026 | 1.84 Mn |
| Dec 31, 2025 | -5.00 Mn |
| Dec 31, 2025 | -5.00 Mn |
| Sep 30, 2025 | 7.00 Mn |
| Sep 30, 2025 | 7.00 Mn |
| Jun 30, 2025 | -7.00 Mn |
| Jun 30, 2025 | -7.00 Mn |
| Mar 31, 2025 | 10.00 Mn |
| Mar 31, 2025 | 10.00 Mn |
| Jun 30, 2024 | 750,000.00 |
| Jun 30, 2024 | 750,000.00 |
| Mar 31, 2024 | 751,000.00 |
| Mar 31, 2024 | 751,000.00 |
| Dec 31, 2023 | 1.07 Mn |
| Dec 31, 2023 | 1.07 Mn |
| Sep 30, 2023 | 825,000.00 |
| Sep 30, 2023 | 825,000.00 |
| Jun 30, 2023 | 487,500.00 |
| Jun 30, 2023 | 487,500.00 |